ArticleJCO precision oncology2025
Reply to: Dihydropyrimidine Dehydrogenase Enzyme-Guided Dosing of 5-Fluorouracil: Prioritizing Precision Over Dose Reduction.
Abstract read
In one paragraph
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Helle-Brit Fiebrich-WestraHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.
Christina HarounHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.
Remco van der GaliënHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.
Daphne den Besten-BertholeeHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.ORCID 0000-0002-7953-1714
Maarten J DeenenHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.ORCID 0000-0002-4389-6420
Dirk Jan A R MoesHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.ORCID 0000-0003-3219-253X
Pierre M BetHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.ORCID 0000-0001-6735-7379
Jan Willem B de GrootHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.
Richard M BrohetHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.ORCID 0000-0003-4472-9322
André B P van KuilenburgHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.
Jan Gerard MaringHelle-Brit Fiebrich-Westra, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Christina Haroun, PharmD, and Remco van der Galiën, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, and Faculty of Pharmaceutical Sciences, University of Groningen, Groningen, NL, Daphne den Besten-Bertholee, PharmD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL, Maarten J. Deenen, PharmD, PhD, Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, NL, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Dirk Jan A.R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, NL, Pierre M. Bet, PharmD, PhD, Department of Clinical Pharmacology & Pharmacy, Amsterdam UMC, Amsterdam, NL, Jan Willem B. de Groot, MD, PhD, Isala Oncology Center, Isala Hospital, Zwolle, NL, Richard M. Brohet, PhD, Department of Epidemiology & Statistics, Isala Hospital, Zwolle, NL, André B.P. van Kuilenburg, PhD, Department of Genetic Metabolic Diseases, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, NL, Jan Gerard Maring, PharmD, PhD, Department of Clinical Pharmacy, Isala Hospital, Zwolle, NL.ORCID 0009-0009-8533-9233
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.